 ImmunityBio Inc NASDAQ: IBRX has revealed early results from its Phase 2 metastatic pancreatic cancer trial QUILT 88, showing that patients overall survival rate doubled compared to the historical survival rate. Phase 2 evaluates the comparative efficacy and overall safety of standard-of-care chemotherapy versus low-dose chemotherapy combined with PD-L1 t-haNK, Anktiva N-803, and aldoxorubicin in locally advanced or metastatic pancreatic cancer. 